Skip to main content



) -- Shares of


(INTC) - Get Intel Corporation Report

leapt in late trades on Thursday after the world's largest chip company

topped Wall Street expectations for its fourth-quarter results

and gave a bullish outlook.

The Dow component reported earnings of $3.4 billion, or 59 cents a share, for the three months ended Dec. 31, up from a year-ago equivalent profit of $3.1 billion, or 51 cents a share, and ahead of the average estimate of analysts polled by

Thomson Reuters

for earnings of 53 cents a share.

Revenue rose 8% year-over-year to $11.46 billion, ahead of the analysts' consensus view of $11.37 billion. For the first quarter, Intel forecast revenue of $11.5 billion, plus or minus $400 million. The current Wall Street projection is for revenue of $10.74 billion in the three-month period ending in March 2011.

Intel shares were last quoted at $21.87, up 2.7%, on volume of nearly 16 million, according to

. The stock is coming off a virtually flat performance in 2010 but there's still a fair amount of bullishness in the analyst community with 29 of the 50 analysts covering the shares at strong buy (13) or buy (buy).

Shares of a number of semiconductor capital equipment and other chip companies were getting a boost in late trades as well following the news, including

TheStreet Recommends

Applied Materials

(AMAT) - Get Applied Materials, Inc. Report

, gaining 5.4% to $15.01 on volume of more than 930,000;


(KLAC) - Get KLA Corporation Report

, adding 5.6% to $41.98 on volume of around 325,000; and

Micron Technology

(MU) - Get Micron Technology, Inc. Report

, which was rising 1.3% to $9.75 on volume of 530,000 after a strong rally in the regular session.


Shares of


(CSTR) - Get CapStar Financial Holdings, Inc. Report

were getting crushed in after-hours action, plunging 25% to $42.70 on volume of 4.1 million after the Bellevue, Wash.-based operator of coin-counting machines and DVD kiosks

made a deep cut to its financial outlook


"This was redbox's first holiday season with 28-day delayed titles, and we underestimated the impact that the delay would have on demand during the fourth quarter," said Paul Davis, the company's CEO, in a statement. "We also expected much better performance from Blu-ray and had purchased to a higher level of demand. While consumer visits to the kiosks remained strong, the number of movies per visit, or basket size, was lower than planned."

Coinstar said it now sees earnings from continuing operations of 65 to 69 cents a share for the December quarter on revenue of $391 million. The company's previous view was for a profit of 79 to 85 cents a share in the quarter on revenue of $415 million to $440 million.

For fiscal 2011, the company said it expects earnings of $2.60 to $3.10 a share on revenue of between $1.7 billion to $1.85 billion, below the current average estimate of analysts polled by

Thomson Reuters

for a profit of $3.34 a share on revenue of $1.88 billion.

Coinstar shares more than doubled in 2010, although the stock did pull back after hitting a 52-week high of $59.43 on June 3. Expectations on Wall Street are high, however, with 12 of the 17 analysts covering the stock at strong buy (6) or buy (6) and the median 12-month price target at $68.50.

Sealy Corp.

Sealy Corp.


was weak after the closing bell after the mattress maker edged past Wall Street's profit expectations for the fourth quarter but missed on the top line.

The company said earnings from continuing operations totaled $3.5 million, or 3 cents a share, coming in a penny ahead of the average estimate of analysts polled by

Thomson Reuters

. Net sales, however, were $296.6 million, roughly flat with the year-ago equivalent performance, and below Wall Street's consensus estimate of $326.1 million.

The stock last changed hands at $2.82, down 5.7%, on volume of around 43,000. The shares are down about 23% over the past year, and six of the eight analysts covering the stock have hold ratings. The other two are at buy.

Cumberland Pharmaceuticals

Shares of

Cumberland Pharmaceuticals

(CPIX) - Get Cumberland Pharmaceuticals Inc. Report

surged in late trades after the company received regulatory approval of a new formulation of its Acetadote Injection, an acetaminophen poisoning treatment.

The stock was last quoted at $6.81, up 20%, on volume of around 25,000, according to

. Based on a regular session close at $5.67, the shares had fallen almost 60% in the past 52 weeks.


Written by Michael Baron in New York.

>To contact the writer of this article, click here:

Michael Baron


>To submit a news tip, send an email to:

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.